DOLORisk: study protocol for a multi-centre observational study to understand the risk factors and determinants of neuropathic pain

Background: Neuropathic pain is an increasingly prevalent condition and has a major impact on health and quality of life. However, the risk factors for the development and maintenance of neuropathic pain are poorly understood. Clinical, genetic and psychosocial factors all contribute to chronic pain, but their interactions have not been studied in large cohorts. The DOLORisk study aims to study these factors. Protocol: Multicentre cross-sectional and longitudinal cohorts covering the main causes leading to neuropathic pain (e.g. diabetes, surgery, chemotherapy, traumatic injury), as well as rare conditions, follow a common protocol for phenotyping of the participants. This core protocol correlates answers given by the participants on a set of questionnaires with the results of their genetic analyses. A smaller number of participants undergo deeper phenotyping procedures, including neurological examination, nerve conduction studies, threshold tracking, quantitative sensory testing, conditioned pain modulation and electroencephalography. Ethics and dissemination: All studies have been approved by their regional ethics committees as required by national law. Results are disseminated through the DOLORisk website, scientific meetings, open-access publications, and in partnership with patient organisations. Strengths and limitations: Large cohorts covering many possible triggers for neuropathic pain Multi-disciplinary approach to study the interaction of clinical, psychosocial and genetic risk factors High comparability of the data across centres thanks to harmonised protocols One limitation is that the length of the questionnaires might reduce the response rate and quality of responses of participants

[1]  P. Schmitz,et al.  Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain‐Barré syndrome , 1991, Muscle & nerve.

[2]  Jacques Fermanian,et al.  Development and validation of the Neuropathic Pain Symptom Inventory , 2004, Pain.

[3]  Daniel J Buysse,et al.  The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. , 2010, Journal of clinical epidemiology.

[4]  Blair H. Smith,et al.  Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) , 2017, International journal of epidemiology.

[5]  Scott R. Bishop,et al.  The Pain Catastrophizing Scale: Development and validation. , 1995 .

[6]  David Yarnitsky,et al.  Recommendations on terminology and practice of psychophysical DNIC testing , 2010, European journal of pain.

[7]  J. Dostrovsky,et al.  Neuropathic pain , 2008, Neurology.

[8]  Jeffrey A. Cohen,et al.  The Reliability and Validity of a Modified Total Neuropathy Score-Reduced and Neuropathic Pain Severity Items When Used to Measure Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Taxanes and Platinums , 2010, Cancer nursing.

[9]  Loriene Roy,et al.  What Is a Reference Source? , 2018, The Reference Librarian.

[10]  G. Gronseth,et al.  Distal symmetric polyneuropathy: A definition for clinical research , 2005, Neurology.

[11]  R. Treede,et al.  Reference data for quantitative sensory testing (QST): Refined stratification for age and a novel method for statistical comparison of group data , 2010, PAIN®.

[12]  M. Nolano,et al.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society , 2010, Journal of the peripheral nervous system : JPNS.

[13]  G. Hall.  Manual of Nerve Conduction Studies , 2001 .

[14]  Alon Sinai,et al.  Pain assessment by continuous EEG: Association between subjective perception of tonic pain and peak frequency of alpha oscillations during stimulation and at rest , 2010, Brain Research.

[15]  Blair H. Smith,et al.  NeuPSIG guidelines on neuropathic pain assessment , 2011, PAIN®.

[16]  DR McCluskey,et al.  Aids to the examination of the peripheral nervous system , 1989, Practical Neurology.

[17]  Ralf Baron,et al.  Deconstructing the Neuropathic Pain Phenotype to Reveal Neural Mechanisms , 2012, Neuron.

[18]  Blair H. Smith,et al.  Neuropathic pain: an updated grading system for research and clinical practice , 2016, Pain.

[19]  Blair H. Smith,et al.  Neuropathic pain in the community: More under-treated than refractory? , 2013, PAIN®.

[20]  Irene Tracey,et al.  Pain vulnerability: a neurobiological perspective , 2014, Nature Neuroscience.

[21]  M B Brown,et al.  A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy , 1994, Diabetes Care.

[22]  Rayaz A. Malik,et al.  Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments , 2010, Diabetes Care.

[23]  F. Birklein,et al.  Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values , 2006, PAIN.

[24]  Bernard Laurent,et al.  Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) , 2005, Pain.

[25]  C. Cleeland,et al.  Pain assessment: global use of the Brief Pain Inventory. , 1994, Annals of the Academy of Medicine, Singapore.

[26]  David Yarnitsky,et al.  Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states , 2010, Current opinion in anaesthesiology.

[27]  Jonathan G. Lees,et al.  The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy , 2016, Pain.

[28]  Archie Campbell,et al.  Cohort Profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its participants and their potential for genetic research on health and illness. , 2013, International journal of epidemiology.

[29]  R. Treede,et al.  Quantitative sensory testing: a comprehensive protocol for clinical trials , 2006, European journal of pain.

[30]  W. Z'Graggen,et al.  Nerve membrane excitability testing , 2008, European journal of anaesthesiology. Supplement.

[31]  S. Gosling,et al.  A very brief measure of the Big-Five personality domains , 2003 .

[32]  B. Perkins,et al.  Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. , 2002, Diabetes care.

[33]  Jonathan G. Lees,et al.  PainNetworks: A web-based resource for the visualisation of pain-related genes in the context of their network associations , 2013, PAIN®.

[34]  Blair H. Smith,et al.  The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. , 2005, The journal of pain : official journal of the American Pain Society.

[35]  D. Yarnitsky,et al.  Recommendations on practice of conditioned pain modulation (CPM) testing , 2015, European journal of pain.

[36]  B. Laurent,et al.  The specific disease burden of neuropathic pain: Results of a French nationwide survey , 2011, PAIN.

[37]  J. Valls-Solé,et al.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Fe‐deration of Neurological Societies and the Peripheral Nerve Society , 2010, European journal of neurology.

[38]  Sooyoung Yoo,et al.  Cerebral peak alpha frequency predicts individual differences in pain sensitivity , 2018, NeuroImage.

[39]  B. Ainsworth,et al.  International physical activity questionnaire: 12-country reliability and validity. , 2003, Medicine and science in sports and exercise.

[40]  D. Burke,et al.  Multiple measures of axonal excitability: A new approach in clinical testing , 2000, Muscle & nerve.

[41]  S. McMahon,et al.  Neurobiological basis for pain vulnerability: why me? , 2017, Pain.

[42]  L. R. Goldberg.  A broad-bandwidth, public domain, personality inventory measuring the lower-level facets of several five-factor models , 1999 .

[43]  T. Jensen,et al.  The evidence for pharmacological treatment of neuropathic pain , 2010, PAIN.

[44]  Blair H. Smith,et al.  Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies: a NeuPSIG systematic review, Delphi survey, and expert panel recommendations , 2015, Pain.

[45]  D. Porteus,et al.  Generation Scotland SFHS Data Dictionary , 2018 .

[46]  Mogher Khamaisi,et al.  Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy , 2012, PAIN.

[47]  S. Dworkin,et al.  Grading the severity of chronic pain , 1992, Pain.

[48]  G. Abecasis,et al.  Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies , 2006, Nature Genetics.

[49]  L. R. Goldberg.  THE DEVELOPMENT OF MARKERS FOR THE BIG-FIVE FACTOR STRUCTURE , 1992 .

[50]  C. Orengo,et al.  Sensory, psychological, and metabolic dysfunction in HIV-associated peripheral neuropathy: A cross-sectional deep profiling study , 2014, PAIN®.

[51]  Blair H. Smith,et al.  Neuropathic pain in the general population: A systematic review of epidemiological studies , 2014, PAIN®.

[52]  R. Baron,et al.  painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain , 2006, Current medical research and opinion.

[53]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[54]  J. Ochoa,et al.  NEUROPATHIC PAIN: REDEFINITION AND A GRADING SYSTEM FOR CLINICAL AND RESEARCH PURPOSES , 2009, Neurology.